Changes in waitlist and posttransplant outcomes in patients with adult congenital heart disease after the new heart transplant allocation system.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
11 2021
Historique:
revised: 14 07 2021
received: 03 05 2021
accepted: 11 08 2021
pubmed: 17 8 2021
medline: 3 2 2022
entrez: 16 8 2021
Statut: ppublish

Résumé

In 2018, the United Network for Organ Sharing (UNOS) introduced new criteria for heart allocation. This study sought to assess the impact of this change on waitlist and posttransplant outcomes in adult congenital heart disease (ACHD) recipients. Between January 2010 and March 2020, we extracted first heart transplant ACHD patients listed from the UNOS database. We compared waitlist and post-transplant outcomes before and after the policy change. A total of 1206 patients were listed, 951 under the old policy and 255 under the new policy. Prior to transplant, recipients under the new policy era were more likely to be treated with extracorporeal membrane oxygenation (P = .018), and have intra-aortic balloon pumps (P < .001), and less likely to have left ventricular assist devices (P = .027).Compared to patients waitlisted in the pre-policy change era, those waitlisted in the post policy change era were more likely to receive transplants (P = .001) with no significant difference in waiting list mortality (P = .267) or delisting (P = .915). There was no difference in 1-year survival post-transplant between the groups (P = .791). The new policy altered the heart transplant cohort in the ACHD group, allowing them to receive transplants earlier with no changes in early outcomes after heart transplantation.

Identifiants

pubmed: 34398487
doi: 10.1111/ctr.14458
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14458

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130:749-756.
Burchill LJ. Heart transplantation in adult congenital heart disease. Heart. 2016;102:1871-1877.
Bhama JK, Shulman J, Bermudez CA, et al. Heart transplantation for adults with congenital heart disease: results in the modern era. J Heart Lung Transplant. 2013;32:499-504.
Kainuma A, Ning Y, Kurlansky PA, et al. Cardiac transplantation in adult congenital heart disease with prior sternotomy. Clin Transplant. 2021;35;e14229.
Kainuma A, Sanchez J, Ning Y, et al. Outcomes of heart transplantation in adult congenital heart disease with prior intracardiac repair. Ann Thorac Surg. 2020:S0003497520314788
Everitt MD, Donaldson AE, Stehlik J, et al. Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). J Heart Lung Transplant. 2011;30:395-401.
Karamlou T, Hirsch J, Welke K, et al. A United Network for Organ Sharing analysis of heart transplantation in adults with congenital heart disease: Outcomes and factors associated with mortality and retransplantation. J Thorac Cardiovasc Surg. 2010;140:161-168.
Davies RR, Russo MJ, Yang J, Quaegebeur JM, Mosca RS, Chen JM. Listing and transplanting adults with congenital heart disease. Circulation. 2011;123:759-767.
Alshawabkeh LI, Hu N, Carter KD, et al. Wait-list outcomes for adults with congenital heart disease listed for heart transplantation in the U.S. J Am Coll Cardiol. 2016;68:908-917.
Givertz MM, DeFilippis EM, Michael J. Landzberg, Pinney SP, Woods RK, Valente AM. Advanced heart failure therapies for adults with congenital heart disease. J Am Coll Cardiol. 2019;74:2295-2312.
Raeisi-Giglou P, Rodriguez ER, Blackstone EH, Tan CD, Hsich EM. Verification of heart disease. JACC Heart Fail. 2017;5:904-913.
Loyaga-Rendon RY, Fermin D, Jani M, et al. Changes in heart transplant waitlist and posttransplant outcomes in patients with restrictive and hypertrophic cardiomyopathy with the new heart transplant allocation system. Am J Transplant. 2021;21:1255-1262.
Jani M, Cook S, Huang SH, et al. Increased frequency of heart transplantation, shortened waitlist time and preserved post-transplant survival in adults with congenital heart disease, on the new heart transplant allocation system. Clin Transplant 2021
Huckaby LV, Seese LM, Mathier MA, Hickey GW, Kilic A. Intra-aortic balloon pump bridging to heart transplantation: impact of the 2018 allocation change. Circ Heart Fail. 2020;13:e006971
Cogswell R, John R, Estep JD, et al. An early investigation of outcomes with the new 2018 donor heart allocation system in the United States. J Heart Lung Transplant. 2020;39:1-4.
Hess NR, Hickey GW, Sultan I, Kilic A. Extracorporeal membrane oxygenation bridge to heart transplant: trends following the allocation change. J Card Surg. 2021;36:40-47.
Chouairi F, Mullan CW, Sen S, et al. Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies PLOS ONE. 2021;16:e0247789
Gelow JM, Song HK, Weiss JB, Mudd JO, Broberg CS. Organ allocation in adults with congenital heart disease listed for heart transplant: Impact of ventricular assist devices. J Heart Lung Transplant. 2013;32:1059-1064.
Khazanie P, Drazner MH. The blurred line between gaming and patient advocacy: heart transplant listing decisions in the modern era. Circulation. 2019;140:2048-2050.
Varshney AS, Berg DD, Katz JN, et al. Use of temporary mechanical circulatory support for management of cardiogenic shock before and after the united network for organ sharing donor heart allocation system changes. JAMA Cardiol. 2020;5:703.
Haranal M, Luo S, Honjo O. Mechanical circulatory support for patients with adult congenital heart disease. Circ J. 2020;84:533-541.
Kirklin JK, Bennett Pearce F, Dabal RJ, Carlo WF. Mechanical circulatory support: strategies and outcomes in pediatric congenital heart disease. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2014;17:62-68.
Nawa S, Sugawara E, Murakami T, Senoo Y, Teramoto S, Morita K. Efficacy of intra-aortic balloon pumping for failing fontan circulation. Chest. 1988;93:599-603.
Moran AM, Blume ED, Quinn R. Intra-aortic balloon pump use in the failing Fontan circulation: intra-aortic balloon pump use in fontan circulation. Congenit Heart Dis. 2008;3:60-62.
Axtell AL, Fiedler AG, Lewis G, et al. Reoperative sternotomy is associated with increased early mortality after cardiac transplantation. Eur J Cardiothorac Surg. 2019;55:1136-1143.
George TJ, Beaty CA, Ewald GA, et al. Reoperative sternotomy is associated with increased mortality after heart transplantation. Ann Thorac Surg. 2012;94:2025-2032.
Still S, Shaikh AF, Qin H, et al. Reoperative sternotomy is associated with primary graft dysfunction following heart transplantation†. Interact Cardiovasc Thorac Surg. 2018;27:343-349.
Ouyang D, Gulati G, Ha R, Banerjee D. Incidence of temporary mechanical circulatory support before heart transplantation and impact on post-transplant outcomes. J Heart Lung Transplant. 2018;37:1060-1066.
Wood KL, Ayers BC, Sagebin F, et al. Complete sternal-sparing heartmate 3 implantation: a case series of 10 consecutive patients. Ann Thorac Surg. 2019;107:1160-1165.
Ayers B, Sagebin F, Wood K, et al. Complete sternal-sparing approach improves outcomes for left ventricular assist device implantation in patients with history of prior sternotomy. Innov Technol Tech Cardiothorac Vasc Surg. 2020;15:51-56.
Castleberry AW, DeVore AD, Southerland KW, et al. Assessing consequences of intraaortic balloon counterpulsation versus left ventricular assist devices at the time of heart transplantation. ASAIO J. 2016;62:232-239.

Auteurs

Atsushi Kainuma (A)

Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Yuming Ning (Y)

Center for Innovation and Outcomes Research, Columbia University, New York, New York, USA.

Paul A Kurlansky (PA)

Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Amy S Wang (AS)

Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Kelly Axom (K)

Department of Medicine/Cardiology, Columbia University Medical Center, New York, New York, USA.

Maryjane Farr (M)

Department of Medicine/Cardiology, Columbia University Medical Center, New York, New York, USA.

Gabriel Sayer (G)

Department of Medicine/Cardiology, Columbia University Medical Center, New York, New York, USA.

Nir Uriel (N)

Department of Medicine/Cardiology, Columbia University Medical Center, New York, New York, USA.

Yoshifumi Naka (Y)

Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Koji Takeda (K)

Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH